[Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study].
In 30 patients with stage NYHA II cardiac insufficiency, a placebo-controlled randomized double-blind study was carried out to determine the efficacy of the Crataegus special extract WS 1442. Treatment duration was 8 weeks, and the substance was administered at a dose of 1 capsule taken twice a day. The main target parameters were alteration in the pressure-x-rate product (PRP) under standardised loading on a bicycle ergometer, and a score of subjective improvement of complaints elicited by a questionnaire. Secondary parameters were exercise tolerance and the change in heart rate and arterial blood pressure. The active substance group showed a statistically significant advantage over placebo in terms of changes in PRP (at a load of 50 W) and the score, but also in the secondary parameter heart rate. In both groups, systolic and diastolic blood pressure was mildly reduced. No adverse reactions occurred.
H
H
Leuchtgens
D000368:Aged; D027825:Crataegus; D004311:Double-Blind Method; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000145:classification / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010936:Plant Extracts; D014665:Vasodilator Agents; C007145:crataegus extract